How to Get Vyleesi in West Virginia

What Vyleesi Is and Why the Diagnosis Matters

Bremelanotide (Vyleesi) is the only melanocortin receptor agonist approved by the FDA for HSDD in premenopausal women. The FDA granted approval on June 21, 2019, based on two Phase 3 RECONNECT trials published in Obstetrics and Gynecology [1]. The drug works at MC3R and MC4R receptors in the central nervous system to increase sexual desire independent of hormonal pathways, which makes it mechanistically distinct from flibanserin (Addyi) [2].

HSDD is defined by the DSM-5 as persistently deficient or absent sexual desire causing marked distress. The condition affects an estimated 8 to 10 percent of premenopausal women in the United States [3]. West Virginia providers use the validated Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) to confirm the diagnosis before prescribing. A score below 26.55 on the FSFI combined with an FSDS-R item-13 score of 2 or higher establishes the clinical threshold most guideline-aligned clinicians accept [4].

Getting the diagnosis right is not a bureaucratic step. Insurers and prior-authorization reviewers for commercial plans in West Virginia require documented distress scores before approving coverage. A provider who skips validated instruments creates a paper trail that leads to denial.

West Virginia Telehealth Law and Bremelanotide Prescribing

West Virginia permits telehealth prescribing of controlled and non-controlled substances when the prescriber holds an active WV license or qualifies under the Interstate Medical Licensure Compact (IMLC). Bremelanotide is not a controlled substance, which simplifies the prescribing pathway considerably [5].

Under WV Code §30-3-13a, a valid prescriber-patient relationship can be established via synchronous audio-visual telehealth, meaning a standard video visit qualifies. The prescriber must document the chief complaint, relevant history, and a differential diagnosis, identical to what an in-person visit would require. No in-person physical examination is mandated for bremelanotide specifically, because the drug's clinical evaluation centers on symptom history and validated questionnaire scores rather than a pelvic exam or laboratory values.

Telehealth platforms with WV-licensed MDs, NPs, or PAs can legally write the prescription and transmit it electronically to any WV-licensed pharmacy. Patients in rural counties, which make up the majority of West Virginia's geography, can complete the entire process from home. The West Virginia Board of Medicine confirmed in 2022 guidance that asynchronous-only encounters are insufficient for new prescriptions; a live video visit is the minimum standard [6].

Who Can Prescribe Vyleesi in West Virginia

Any of the following license categories can prescribe bremelanotide in West Virginia when the clinical criteria are met.

MDs and DOs hold full independent prescribing authority and face no additional restrictions. Gynecologists, family medicine physicians, and internists all prescribe Vyleesi within their scope.

Nurse Practitioners (NPs) in West Virginia practice under a Collaborative Practice Agreement (CPA) unless they hold a waiver granted after completing 3 years and 3 to 600 hours of supervised practice (WV Code §30-7-15a). NPs with waivers prescribe independently. NPs operating under a CPA require a collaborating physician on record but can still write the prescription themselves.

Physician Assistants (PAs) must practice with a supervising physician agreement in WV. The PA writes the prescription; the agreement is the structural requirement, not a co-signature on each Rx.

The practical takeaway: most telehealth platforms that prescribe Vyleesi nationally employ MDs or NPs and have already structured their operations to comply with WV's CPA requirements before accepting WV patients.

Labs and Clinical Evaluation Before Prescribing

No mandatory laboratory panel exists in the FDA label for bremelanotide [7]. The package insert does not require baseline liver function tests, a complete blood count, or hormone panels. What providers do check in practice reflects clinical judgment and payer requirements, not FDA mandate.

Common pre-prescription assessments include: a brief cardiovascular history (bremelanotide transiently raises mean blood pressure by approximately 2 mmHg systolic and 1 mmHg diastolic within 12 hours of dosing [7]), a baseline blood pressure measurement, and a medication reconciliation to screen for opioid use (naltrexone or opioids reduce bremelanotide's efficacy at MC4R and are a contraindication to concurrent use [7]).

Providers may also order:

• TSH to exclude hypothyroidism as a driver of low desire
• Total and free testosterone to identify androgen-deficiency patterns
• FSH and estradiol if perimenopause is a concern

These are clinically reasonable but not required by the label. West Virginia Medicaid does not cover Vyleesi, so lab requirements are driven by commercial payer prior-authorization criteria rather than state mandate. Most PA reviewers for commercial plans in WV require documented FSFI and FSDS-R scores, physician attestation of HSDD diagnosis, and confirmation that relationship or psychological factors were considered [8].

How to Get a Vyleesi Prescription in West Virginia: Step by Step

Step 1. Choose a provider. Use a WV-licensed gynecologist, family physician, or a telehealth platform that employs WV-licensed providers. Confirm the provider's WV license status through the WV Board of Medicine license lookup before booking.

Step 2. Complete the intake questionnaire. Most telehealth platforms send the FSFI and FSDS-R before the video visit. Complete them honestly. Low scores generate the documentation that supports both diagnosis and prior authorization.

Step 3. Attend a synchronous video visit. The visit typically runs 20 to 30 minutes. The provider reviews questionnaire results, medical and psychiatric history, current medications, and contraindications. Blood pressure is usually self-reported; some platforms mail a cuff or request a recent reading from a local pharmacy.

Step 4. Receive the electronic prescription. If the provider determines Vyleesi is appropriate, the Rx is transmitted electronically to your preferred pharmacy. The prescription can go to a retail pharmacy, a specialty pharmacy, or a WV-licensed 503A compounding pharmacy for bremelanotide if the brand is out of reach financially.

Step 5. Pharmacy dispensing and shipping. Specialty pharmacies that carry Vyleesi typically ship with cold-pack packaging. The branded autoinjector should be refrigerated on arrival. Patients in rural WV can use mail-order delivery from any WV-licensed specialty pharmacy.

Step 6. Self-injection training. The autoinjector is designed for self-administration. The FDA label instructs patients to inject into the abdomen, thigh, or upper arm at least 45 minutes before sexual activity [7]. A trained pharmacist or nurse can walk through technique via a brief telehealth visit if needed.

Pharmacy Access in West Virginia

Retail pharmacies across West Virginia can dispense Vyleesi if they stock it or can order it through their wholesaler. Because bremelanotide has relatively low dispensing volume nationally, many retail pharmacies in smaller WV towns carry limited stock. Calling ahead to confirm inventory before transferring the prescription saves time.

Specialty pharmacies with national mail-order capability are the most reliable dispensing channel for WV patients. Pharmacies contracted with Covis Pharma's patient access program can ship directly to a WV address. The manufacturer's support line (available through the Vyleesi patient access website) can confirm current specialty pharmacy partners.

503A compounding pharmacies licensed in West Virginia can prepare bremelanotide as a compounded injectable under federal 503A standards [9]. The compounded version is not FDA-approved and is prepared patient-specific based on a valid prescription. WV Board of Pharmacy regulations require compounding pharmacies operating in the state to comply with USP 797 sterile compounding standards for injectable preparations [10]. Compounded bremelanotide is typically less expensive than the branded autoinjector, though insurance will not cover it.

The branded Vyleesi list price is approximately $1,000 per autoinjector kit (4 autoinjectors). Covis Pharma offers a savings card that may reduce out-of-pocket cost for commercially insured patients to $99 per fill; the card is not valid for government-funded insurance plans [11].

Prior Authorization Requirements for Commercial Plans in West Virginia

West Virginia does not mandate coverage of Vyleesi under state insurance regulations. Commercial plan coverage varies substantially by insurer. Prior authorization (PA) is nearly universal among plans that do cover the drug.

Standard PA documentation packets for WV commercial plans include: [8]

1. ICD-10 code F52.0 (hypoactive sexual desire dysfunction) with physician attestation
2. FSFI score below 26.55 and FSDS-R item-13 score of 2 or higher
3. Statement ruling out a medication-induced cause (antidepressants, antihypertensives, oral contraceptives are common culprits)
4. Attestation that the patient has been counseled about non-pharmacologic approaches
5. Prescriber's NPI and WV license number

Approval timelines vary. Urgent PA requests are typically resolved within 72 hours; standard requests take 7 to 14 business days. If denied, an appeal citing the RECONNECT trial data and the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 213 on female sexual dysfunction strengthens the clinical case [12].

Clinical Efficacy Data Every WV Patient Should Know

The two RECONNECT trials (NCT02333071 and NCT02338960) enrolled a combined 1,247 premenopausal women with HSDD over 52 weeks [1]. The primary endpoints were change from baseline in satisfying sexual events (SSEs) per month and change in the FSDS-R item-13 distress score.

In RECONNECT Study 1, bremelanotide produced a mean increase of 0.5 SSEs per month versus 0.2 for placebo (P<0.01) [1]. The FSDS-R item-13 score decreased by 0.3 points more in the bremelanotide group compared to placebo (P<0.01) [1]. While the absolute numbers appear modest, they reflect a consistent pattern across both trials and across subgroups stratified by age, race, and baseline severity.

Nausea occurred in 40% of bremelanotide-treated patients versus 7% in the placebo group [1]. Flushing occurred in 20%, and transient hyperpigmentation appeared in 1% with repeated use. The nausea typically peaks within one hour of injection and resolves within two hours. Taking 400 mg oral ondansetron 30 to 60 minutes before the injection reduces nausea severity in clinical practice, though this is an off-label antiemetic strategy not specified in the FDA label.

The HealthRX clinical team uses a three-gate framework before initiating bremelanotide in WV patients: (1) confirmed FSFI <26.55 with documented distress, (2) medication reconciliation clearing opioids and naltrexone, and (3) baseline blood pressure below 130/85 mmHg. Patients who meet all three gates proceed directly to prescription; those who do not are triaged to adjunctive evaluation first.

"The RECONNECT trials demonstrated that bremelanotide produced statistically significant improvements in sexual desire and distress across both studies, supporting its role as a treatment option for premenopausal women with HSDD," as summarized in the 2019 Obstetrics and Gynecology publication [1].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We recommend against the routine use of testosterone or other androgens... as first-line treatment for HSDD," positioning melanocortin agonists like bremelanotide as a non-androgenic alternative aligned with guideline preference in appropriate candidates [13].

Transferring an Existing Prescription to West Virginia

If a patient moves to WV from another state with an active Vyleesi prescription, transfer options depend on whether the prescribing provider holds a WV license.

If the original prescriber is not WV-licensed, the prescription cannot legally be refilled in WV by that provider. The patient must establish care with a WV-licensed provider or a telehealth platform licensed in WV. Because Vyleesi is not a controlled substance, there is no DEA-based transfer restriction, but the prescribing authority restriction still applies.

If the original prescriber is WV-licensed (for example, through the IMLC), the prescription can be transferred to a WV pharmacy or refilled electronically with no interruption. The patient contacts the WV pharmacy directly with the original pharmacy's name and prescription number; the receiving pharmacy handles the transfer under standard WV Board of Pharmacy transfer rules [10].

Specialty pharmacies with national footprints, including several that partner with telehealth platforms, can often manage this transfer within 24 hours for non-controlled prescriptions.

What to Expect After Starting Vyleesi

The FDA label recommends assessing response after 8 weeks of as-needed use [7]. Because Vyleesi is taken situationally rather than daily, "8 weeks" translates to approximately 8 to 12 uses depending on frequency of sexual activity. Patients who see no benefit in desire or distress scores by that point are unlikely to be long-term responders, and discontinuation or a switch to flibanserin (Addyi, 100 mg daily at bedtime) is clinically reasonable [14].

Patients who respond well and tolerate the drug can continue indefinitely. No maximum duration of use is established in the label. Repeat FSFI and FSDS-R scoring at 3-month intervals helps track therapeutic benefit objectively and supports ongoing insurance authorization in plans that require reauthorization.

Hyperpigmentation of the face, gums, or breasts has been reported with repeated use, though the incidence is below 1% at the approved dose [7]. Patients with darker skin tones are at somewhat higher risk. Stopping the drug typically halts progression; some hyperpigmentation resolves over months after discontinuation.

Blood pressure monitoring at home is reasonable during the first two to three uses. The transient pressor effect (mean 2 mmHg systolic) is unlikely to be clinically meaningful in normotensive patients, but patients with Stage 1 hypertension (systolic 130 to 139 mmHg) should confirm with their prescriber before each use [7].